全部商品分类
用小程序，查商品更便捷
FCM
1:500
The cluster of differentiation 20 (CD20, aka Ly-44, or B-lymphocyte antigen) is a ~35 KDa cell surface protein mainly expressed by resting and activated B lymphocytes, but not plasma cells [1]. CD20 is also expressed by most malignant B cells, which makes it an ideal target for antibody-based immunotherapies against lymphoid malignancies [1-4]. For example, Rituximab, Obinutuzumab, and Ofatumumab are FDA-approved monoclonal anti-human CD20 antibodies for the treatment of B-cell non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia [1-4]. These antibodies mediate the target cell destruction through different mechanisms including direct signaling of apoptosis, complement activation (CDC), and cell-mediated cytotoxicity (ADCC).
The anti-mCD20 18B12 mAb is commonly used for in vivo depletion of the CD20+ B cell population to study the role of B cells in various immune responses, including auto-immune or tumoral contexts [1, 7].
Anti-mCD20-mIgG2a is provided in an Invivo grade, a high-quality standard specifically adapted to in vivo studies.
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
参考图片
Flow cytometric analysis of mouse primary splenocytes labeling CD20 with purified antibody at 1/500 dilution (1 μg) (Right) compared with a Mouse monoclonal IgG isotype control (Left). Goat Anti-Mouse IgG Alexa Fluor® 488 was used as the secondary antibody.
Cells were surface stained with CD3-Alexa Fluor® 647, then stained with rabbit IgG (Left) / anti-CD20 (Right) separately. CD3 and CD20 are mutually exclusive expressed in mouse primary splenocytes. Gated on total viable cells.